Conference Coverage

Complete Conference Coverage

Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma

Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma

Compared with sorafenib, tivozanib was associated with improved progression-free survival and objective response rate, researchers reported.

First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC

First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC

About 25% of patients with previously untreated advanced non-clear cell renal cell carcinoma had an objective response to pembrolizumab.

Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma

Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma

Avelumab-axitinib regimen offers better progression-free survival and responses than sunitinib for patients with previously untreated advanced RCC, regardless of risk group or PD-L1 status.

Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma

Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma

New analysis shows that early tumor shrinkage with cabozantinib is associated with longer survival compared with everolimus.

Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed

Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed

Patients with treatment-naive, intermediate- and poor-risk advanced RCC continue to have superior overall survival with the dual ICI regimen compared with sunitinib alone.

Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma

Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma

As first-line therapy for locally advanced or metastatic renal cell carcinoma, pembrolizumab plus axitinib offers longer overall and progression-free survival compared with sunitinib.

Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma

Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma

Postoperative radiation therapy with adjuvant chemotherapy prolonged disease-free survival and overall survival in patients with locally advanced urothelial carcinoma.

Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma

Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma

In a study of patients receiving non-surgical treatment for localized upper tract urothelial carcinoma, radiation or chemotherapy provided no overall survival benefit.

Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer

Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer

Trimodal therapy for patients with muscle-invasive bladder cancer is associated with worse cancer-specific and overall survival and higher costs compared with radical cystectomy.

Pembrolizumab Shows Promise for BCG-Unresponsive Bladder Cancer

Pembrolizumab Shows Promise for BCG-Unresponsive Bladder Cancer

Pembrolizumab, a PD-1 inhibitor, demonstrated antitumor activity in patients with high-risk BCG-unresponsive carcinoma in situ.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs